| Autor: |
Tal-Singer R; COPD Foundation, Research Department, Washington, DC., Yawn BP; COPD Foundation, Research Department, Washington, DC.; University of Minnesota, Family and Community Health, Minneapolis., Wise R; Pulmonary and Critical Care, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland., Thomashow BM; COPD Foundation, Research Department, Washington, DC.; Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University, New York, New York., Boyce DM; COPD Foundation, Research Department, Washington, DC. |
| Jazyk: |
angličtina |
| Zdroj: |
Chronic obstructive pulmonary diseases (Miami, Fla.) [Chronic Obstr Pulm Dis] 2020 Jul; Vol. 7 (3), pp. 139-146. |
| DOI: |
10.15326/jcopdf.7.3.2020.0164 |
| Abstrakt: |
Competing Interests: Dr. Tal-Singer is a former employee and current shareholder of GlaxoSmithKline and has received personal fees from Vocalis Health and Immunomet outside of the submitted work. Dr. Yawn reports personal fees and non-financial support from Boehringer Ingelheim and personal fees from AstraZeneca, GlaxoSmithKline, and Novartis outside the submitted work. Dr. Thomashow is co-founder and former Chair of the Board of Directors for the COPD Foundation and currently serves as its Chief Medical Officer. He has served as a consultant for Boehringer Ingelheim and served on advisory boards for GlaxoSmithKline and AstraZeneca. Dr. Wise reports grants and personal fees from AstraZeneca/Medimmune, GlaxoSmithKline, Novartis and Boehringer-Ingelheim, personal fees from Contrafect, PulmonX, Roche / Genentech, Spiration, Pneuma, Verona, Bonti, Denali, Aradigm, Mylan, Theravance, Propeller Health, Kiniksa, Sunovion, Merck, and Circassia; and grants from Pearl Therapeutics, outside the submitted work. Ms. Boyce has nothing to declare. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
